

Ref: 21411/0253/001-0001

Date: 11.11.2019

Medicines and Healthcare products Regulatory Agency
10 S Colonnade,
Canary Wharf,
London,
E14 4PU

Castle Hill Hospital
Castle Road
Cottingham
East Yorkshire
HU16 5JQ

Tel: 01482 461903
Email: james.illingworth@hey.nhs.uk

Dear MHRA

Trial title: AX-8 - Prospective, multi-centre, randomised, placebo-controlled, double-blind, cross-over, phase IIa proof-of-concept trial to investigate the efficacy and safety of AX-8 tablets 5 mg in patients with chronic refractory cough and associated upper airway symptoms.		
EudraCT no: 2016-004803-30	IRAS project ID: 210459	Sponsor R&D ref no: R2060
Participating site: Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ		Principal investigator: Professor Alyn Morice

This is to notify you that the above study terminated in the set up phase.

The board of directors of the company developing AX-8 decided to stop this clinical trial at the set-up phase as there were significant doubts as to whether the adapted study design (as a result of the MHRA non-acceptance letter) would provide robust study results.

Furthermore, the phase 1 trial which showed unexpectedly systemic bioavailability of the drug, would require a considerably more extensive development program than originally planned.

Yours sincerely



James Illingworth
R&D Manager